Cargando…
Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290884/ https://www.ncbi.nlm.nih.gov/pubmed/35855458 http://dx.doi.org/10.1093/nop/npac022 |
_version_ | 1784749013437775872 |
---|---|
author | Caramanna, Ivan de Kort, Julie M Brandes, Alba A Taal, Walter Platten, Michael Idbaih, Ahmed Frenel, Jean Sebastien Wick, Wolfgang Preetha, Chandrakanth Jayachandran Bendszus, Martin Vollmuth, Philipp Reijneveld, Jaap C Klein, Martin |
author_facet | Caramanna, Ivan de Kort, Julie M Brandes, Alba A Taal, Walter Platten, Michael Idbaih, Ahmed Frenel, Jean Sebastien Wick, Wolfgang Preetha, Chandrakanth Jayachandran Bendszus, Martin Vollmuth, Philipp Reijneveld, Jaap C Klein, Martin |
author_sort | Caramanna, Ivan |
collection | PubMed |
description | BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment. METHODS: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery. The battery is comprised of the Hopkins Verbal Learning Test—Revised (HVLT-R), Controlled Oral Word Association Test (COWA), and Trail Making Test (A and B). RESULTS: Out of 321 patients, 148 (46.1%) were not using corticosteroids, and 173 were using dexamethasone (34.3%), methylprednisolone (9.7%), or other corticosteroids (9.9%). Patients on corticosteroids had worse performance on all neurocognitive tests. Regression analyses demonstrated a negative association between corticosteroids use and the HVLT-R free recall score (R(2) change = 0.034, F change (1, 272) = 13.392, P < .001) and HVLT-R Delayed Recall score (R(2) change = 0.028, F change (1, 270) = 10.623, P = .002). No statistically significant association was found for HVLT-R Delayed recognition, COWA, TMT part A and TMT part B (P > .05). CONCLUSIONS: Glioblastoma patients prescribed with corticosteroids show poorer memory functions, expressive language, visual-motor scanning speed, and executive functioning than patients not using corticosteroids. Furthermore, we found a negative association between corticosteroid intake and memory functions. The possibility of deleterious effects of corticosteroids on NCF should be considered during clinical decision making. |
format | Online Article Text |
id | pubmed-9290884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92908842022-07-18 Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 Caramanna, Ivan de Kort, Julie M Brandes, Alba A Taal, Walter Platten, Michael Idbaih, Ahmed Frenel, Jean Sebastien Wick, Wolfgang Preetha, Chandrakanth Jayachandran Bendszus, Martin Vollmuth, Philipp Reijneveld, Jaap C Klein, Martin Neurooncol Pract Original Articles BACKGROUND: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment. METHODS: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery. The battery is comprised of the Hopkins Verbal Learning Test—Revised (HVLT-R), Controlled Oral Word Association Test (COWA), and Trail Making Test (A and B). RESULTS: Out of 321 patients, 148 (46.1%) were not using corticosteroids, and 173 were using dexamethasone (34.3%), methylprednisolone (9.7%), or other corticosteroids (9.9%). Patients on corticosteroids had worse performance on all neurocognitive tests. Regression analyses demonstrated a negative association between corticosteroids use and the HVLT-R free recall score (R(2) change = 0.034, F change (1, 272) = 13.392, P < .001) and HVLT-R Delayed Recall score (R(2) change = 0.028, F change (1, 270) = 10.623, P = .002). No statistically significant association was found for HVLT-R Delayed recognition, COWA, TMT part A and TMT part B (P > .05). CONCLUSIONS: Glioblastoma patients prescribed with corticosteroids show poorer memory functions, expressive language, visual-motor scanning speed, and executive functioning than patients not using corticosteroids. Furthermore, we found a negative association between corticosteroid intake and memory functions. The possibility of deleterious effects of corticosteroids on NCF should be considered during clinical decision making. Oxford University Press 2022-03-13 /pmc/articles/PMC9290884/ /pubmed/35855458 http://dx.doi.org/10.1093/nop/npac022 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Caramanna, Ivan de Kort, Julie M Brandes, Alba A Taal, Walter Platten, Michael Idbaih, Ahmed Frenel, Jean Sebastien Wick, Wolfgang Preetha, Chandrakanth Jayachandran Bendszus, Martin Vollmuth, Philipp Reijneveld, Jaap C Klein, Martin Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title_full | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title_fullStr | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title_full_unstemmed | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title_short | Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101 |
title_sort | corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: evidence from european organization for research and treatment of cancer (eortc) trial 26101 |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290884/ https://www.ncbi.nlm.nih.gov/pubmed/35855458 http://dx.doi.org/10.1093/nop/npac022 |
work_keys_str_mv | AT caramannaivan corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT dekortjuliem corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT brandesalbaa corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT taalwalter corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT plattenmichael corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT idbaihahmed corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT freneljeansebastien corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT wickwolfgang corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT preethachandrakanthjayachandran corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT bendszusmartin corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT vollmuthphilipp corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT reijneveldjaapc corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 AT kleinmartin corticosteroidsuseandneurocognitivefunctioninginpatientswithrecurrentglioblastomaevidencefromeuropeanorganizationforresearchandtreatmentofcancereortctrial26101 |